SCHEMBL12518166

SCHEMBL12518166

CCCCCCCCCCCCCCOC(=O)CC(OP(=O)(O)O)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 3/20 0.49
NAAA Q02083 1/20 0.49
LPAR3 Q9UBY5 3/20 0.45
LPAR1 Q92633 2/20 0.45
LPAR2 Q9HBW0 2/20 0.45
P2RY10 O00398 4/20 0.44
GPR34 Q9UPC5 2/20 0.44
PLA2G2A P14555 2/20 0.43
RAD52 P43351 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5571344 0.81 SMPD1 (0.62) SMPD1
SCHEMBL5574626 0.81 SMPD1 (0.62) SMPD1
SCHEMBL5573002 0.81 SMPD1 (0.62) SMPD1
SCHEMBL5575193 0.81 SMPD1 (0.62) SMPD1
SCHEMBL18339529 0.81 SMPD1 (0.62) SMPD1
SCHEMBL28746443 0.80 SMPD1 (0.57) SMPD1NAAALPAR3LPAR1LPAR2
SCHEMBL460132 0.78 NAAA (0.47) NAAARAD52NPSR1
SCHEMBL22915292 0.78 NAAA (0.50) NAAARAD52NPSR1
SCHEMBL28565643 0.77 NAAA (0.62) NAAARAD52NPSR1
SCHEMBL9295177 0.77 NAAA (0.49) NAAARAD52NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220265543-A1 COSMETIC COMPOSITIONS AND USES THEREOF ALUMIER LABS, INC. (CA) 2022-08-25 US disclosed
EP-4003274-A1 COSMETIC COMPOSITIONS COMPRISING PLANT EXTRACTS AND USES THEREOF Alumier Europe Limited (MT) 2022-06-01 EP disclosed
WO-2021013973-A1 COSMETIC COMPOSITIONS COMPRISING PLANT EXTRACTS AND USES THEREOF ALUMIER EUROPE LIMITED (MT) 2021-01-28 WO disclosed
EP-2525774-B1 NEW LIPO-PHOSPHATED OR LIPO-SULPHATED COMPOUND, COMPOSITIONS COMPRISING IT AND TOPICAL USES THEREOF SEDERMA SA (FR) 2016-03-30 EP disclosed
US-20130004439-A1 Lipo-Phosphated or Lipo-Sulphated Compound, Compositions Comprising It and Topical Uses Thereof SEDERMA, S.A.S. (FR) 2013-01-03 US disclosed
US-20130004439-A1 Lipo-Phosphated or Lipo-Sulphated Compound, Compositions Comprising It and Topical Uses Thereof SEDERMA, S.A.S. (FR) 2013-01-03 US disclosed
WO-2011086532-A1 NEW LIPO-PHOSPHATED OR LIPO-SULPHATED COMPOUND, COMPOSITIONS COMPRISING IT AND TOPICAL USES THEREOF SEDERMA (FR) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220265543-A1 COSMETIC COMPOSITIONS AND USES THEREOF CUTA, CERS2, GLA SMPD1 67/4885NAAA 852/4885LPAR3 863/4885
US-20130004439-A1 Lipo-Phosphated or Lipo-Sulphated Compound, Compositions Comprising It and Topical Uses Thereof LOXL3, CUTA, LOXL4 SMPD1 994/4885NAAA 625/4885LPAR3 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.